Peptomyc — Series A (estimated) · €5.7M

Peptomyc closed a €5M equity round to move its MYC inhibitor OMO-103 to the next stage of development. The money goes to finishing ongoing clinical studies, getting manufacturing ready for later-stage trials, and partnering talks. Alta Life Sciences and AurorA Science co-led the round. New investors EIC Fund and Laudecum joined, and CDTI Innovación invested again through SICC Innvierte. The company did not give the round a stage name.

LeadAlta Life Sciences, AurorA Science RoundSeries A (estimated) Announced24 Mar 2026 CityBarcelona SectorHealthtech & Bio · Biotech Source P

Extended 29 Sep 2026: +€0.7M from Institut Català de Finances (ICF)

Something wrong? Suggest a correction →